Carl Watson Selected Research

emactuzumab

1/2022	Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
1/2021	Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition.
10/2020	Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carl Watson Research Topics

Disease

2	Fatigue 01/2022 - 10/2020
2	Neoplasms (Cancer) 01/2022 - 10/2020
2	Edema (Dropsy) 01/2021 - 10/2020
1	Exanthema (Rash) 01/2022
1	Body Weight (Weight, Body) 01/2021
1	Giant Cell Tumors (Giant Cell Tumor) 01/2021
1	Cholesteatoma 12/2014

Drug/Important Bio-Agent (IBA)

3	emactuzumabIBA 01/2022 - 10/2020
2	Monoclonal AntibodiesIBA 01/2022 - 10/2020
2	Macrophage Colony-Stimulating FactorIBA 01/2021 - 10/2020
1	atezolizumabIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	LigandsIBA 01/2022
1	Peptide Hydrolases (Proteases)FDA Link 01/2021
1	Proteoglycans (Proteoglycan)IBA 01/2021
1	Biological ProductsIBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	Matrix Metalloproteinases (MMPs)IBA 01/2021
1	CreatinineIBA 10/2020
1	selicrelumabIBA 10/2020
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 10/2020

Therapy/Procedure

1	Mastoidectomy 12/2014